May 3, 2024
Congratulations to the team at the North West Cancer Centre, opening CAPItello-292: A Phase Ib/III, Open-label, Randomised Study of Capivasertib plus CDK4/6 Inhibitors and Fulvestrant versus CDK4/6 Inhibitors and Fulvestrant in Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Locally Advanced, Unresectable or Metastatic Breast Cancer. The Principal Investigator is Dr Conor O’Neill.